{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:52Z","timestamp":1791619012867,"version":"4.3.4"},"publisher-location":"Cham","reference-count":101,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030793074","type":"print"},{"value":"9783030793081","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-79308-1_13","type":"book-chapter","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T20:02:45Z","timestamp":1640980965000},"page":"339-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatobiliary and Pancreatic Adverse Events"],"prefix":"10.1007","author":[{"given":"Hao Chi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan Sun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"issue":"1","key":"13_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit, T. B., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R. (2020). Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology, 72(1), 315\u2013329. Epub 2020\/03\/14.","journal-title":"Hepatology"},{"key":"13_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M., Bigenwald, C., Champiat, S., et al. (2016). Immune-related adverse events with immune checkpoint blockade: A comprehensive review. European Journal of Cancer, 54, 139\u2013148. Epub 2016\/01\/15.","journal-title":"European Journal of Cancer"},{"issue":"10","key":"13_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian, S. L., Sznol, M., McDermott, D. F., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020\u20131030. Epub 2014\/03\/05.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"13_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","volume":"23","author":"SG Bernardo","year":"2013","unstructured":"Bernardo, S. G., Moskalenko, M., Pan, M., et al. (2013). Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Research, 23(1), 47\u201354. Epub 2012\/12\/25.","journal-title":"Melanoma Research"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain, L., Diem, S., & Larkin, J. (2016). Management of toxicities of immune checkpoint inhibitors. Cancer Treatment Reviews, 44, 51\u201360. Epub 2016\/02\/15.","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"13_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine, 373(1), 23\u201334. Epub 2015\/06\/02.","journal-title":"The New England Journal of Medicine"},{"issue":"10105","key":"13_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter, J., Ribas, A., Long, G. V., et al. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 390(10105), 1853\u20131862. Epub 2017\/08\/22.","journal-title":"Lancet"},{"issue":"4","key":"13_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Long, G. V., Brady, B., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 372(4), 320\u2013330. Epub 2014\/11\/18.","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"13_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S., D\u2019Angelo, S. P., Minor, D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375\u2013384. Epub 2015\/03\/22.","journal-title":"The Lancet Oncology"},{"issue":"21","key":"13_CR10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B., Rizvi, N. A., Hui, R., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine, 372(21), 2018\u20132028. Epub 2015\/04\/22.","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"13_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C., Tarhini, A., Routier, E., et al. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 13(8), 473\u2013486. Epub 2016\/05\/05.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"34","key":"13_CR12","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol, M., Ferrucci, P. F., Hogg, D., et al. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. Journal of Clinical Oncology, 35(34), 3815\u20133822. Epub 2017\/09\/16.","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"13_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin, E., Michot, J. M., Papouin, B., et al. (2018). Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology, 68(6), 1181\u20131190. Epub 2018\/02\/11.","journal-title":"Journal of Hepatology"},{"issue":"2","key":"13_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","volume":"115","author":"ED Miller","year":"2020","unstructured":"Miller, E. D., Abu-Sbeih, H., Styskel, B., et al. (2020). Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. The American Journal of Gastroenterology, 115(2), 251\u2013261. Epub 2019\/12\/04.","journal-title":"The American Journal of Gastroenterology"},{"issue":"4","key":"13_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim, K. W., Ramaiya, N. H., Krajewski, K. M., et al. (2013). Ipilimumab associated hepatitis: Imaging and clinicopathologic findings. Investigational New Drugs, 31(4), 1071\u20131077. Epub 2013\/02\/15.","journal-title":"Investigational New Drugs"},{"issue":"21","key":"13_CR16","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber, J. S., K\u00e4hler, K. C., & Hauschild, A. (2012). Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 30(21), 2691\u20132697. Epub 2012\/05\/23.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"13_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1148\/rg.352140121","volume":"35","author":"JJ Kwak","year":"2015","unstructured":"Kwak, J. J., Tirumani, S. H., Van den Abbeele, A. D., Koo, P. J., & Jacene, H. A. (2015). Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics, 35(2), 424\u2013437. Epub 2015\/03\/13.","journal-title":"Radiographics"},{"issue":"8","key":"13_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day, S. J., Maio, M., Chiarion-Sileni, V., et al. (2010). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Annals of Oncology, 21(8), 1712\u20131717. Epub 2010\/02\/12.","journal-title":"Annals of Oncology"},{"issue":"8","key":"13_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla, M., Misdraji, J., Pratt, D. S., et al. (2015). Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. The American Journal of Surgical Pathology, 39(8), 1075\u20131084. Epub 2015\/06\/03.","journal-title":"The American Journal of Surgical Pathology"},{"issue":"9","key":"13_CR20","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","volume":"29","author":"KD Chmiel","year":"2011","unstructured":"Chmiel, K. D., Suan, D., Liddle, C., et al. (2011). Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. Journal of Clinical Oncology, 29(9), e237\u2013e240. Epub 2011\/01\/12.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"13_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","volume":"19","author":"P Cramer","year":"2017","unstructured":"Cramer, P., & Bresalier, R. S. (2017). Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Current Gastroenterology Reports, 19(1), 3. Epub 2017\/01\/27.","journal-title":"Current Gastroenterology Reports"},{"issue":"17","key":"13_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology, 36(17), 1714\u20131768. Epub 2018\/02\/15.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"13_CR23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016). Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncology, 2(10), 1346\u20131353. Epub 2016\/07\/02.","journal-title":"JAMA Oncology"},{"issue":"3","key":"13_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki, A., Brunt, E. M., Kleiner, D. E., et al. (2011). The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 54(3), 931\u2013939. Epub 2011\/06\/16.","journal-title":"Hepatology"},{"key":"13_CR25","unstructured":"Institute NIoH-NC. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute: National Cancer Institute; 2017 [cited 2021 28 Feb]; 5.0. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"13_CR26","doi-asserted-by":"crossref","unstructured":"Gonzalez, H., Imam, Z., Wong, R., et al. (2020). Normal alkaline phosphatase levels are dependent on race\/ethnicity: National GEP Health and Nutrition Examination Survey data. BMJ Open Gastroenterol, 7(1) Epub 2020\/10\/16.","DOI":"10.1136\/bmjgast-2020-000502"},{"issue":"1","key":"13_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes, E. M., Zeniya, M., Czaja, A. J., et al. (2008). Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 48(1), 169\u2013176. Epub 2008\/06\/10.","journal-title":"Hepatology"},{"issue":"4","key":"13_CR28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1148\/rg.244035719","volume":"24","author":"KJ Mortele","year":"2004","unstructured":"Mortele, K. J., Segatto, E., & Ros, P. R. (2004). The infected liver: Radiologic-pathologic correlation. Radiographics, 24(4), 937\u2013955. Epub 2004\/07\/17.","journal-title":"Radiographics"},{"issue":"11","key":"13_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","volume":"5","author":"G Widmann","year":"2016","unstructured":"Widmann, G., Nguyen, V. A., Plaickner, J., & Jaschke, W. (2016). Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Current Radiology Reports, 5(11), 59. Epub 2016\/01\/01.","journal-title":"Current Radiology Reports"},{"issue":"7","key":"13_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/apt.15413","volume":"50","author":"I Tsung","year":"2019","unstructured":"Tsung, I., Dolan, R., Lao, C. D., et al. (2019). Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Alimentary Pharmacology & Therapeutics, 50(7), 800\u2013808. Epub 2019\/07\/17.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"7","key":"13_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","volume":"72","author":"F Alessandrino","year":"2017","unstructured":"Alessandrino, F., Tirumani, S. H., Krajewski, K. M., et al. (2017). Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: Chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clinical Radiology, 72(7), 521\u2013533. Epub 2017\/05\/10.","journal-title":"Clinical Radiology"},{"issue":"10","key":"13_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani, S. H., Ramaiya, N. H., Keraliya, A., et al. (2015). Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunology Research, 3(10), 1185\u20131192. Epub 2015\/06\/24.","journal-title":"Cancer Immunology Research"},{"key":"13_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017). Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacology, 8, 49. Epub 2017\/02\/24.","journal-title":"Frontiers in Pharmacology"},{"issue":"8","key":"13_CR34","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner, D. E., & Berman, D. (2012). Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Digestive Diseases and Sciences, 57(8), 2233\u20132240. Epub 2012\/03\/22.","journal-title":"Digestive Diseases and Sciences"},{"issue":"3","key":"13_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A., Schneider, B. J., Brahmer, J., et al. (2020). NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230\u2013241. Epub 2020\/03\/07.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"13_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","volume":"41","author":"J Everett","year":"2017","unstructured":"Everett, J., Srivastava, A., & Misdraji, J. (2017). Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. The American Journal of Surgical Pathology, 41(1), 134\u2013137. Epub 2016\/10\/30.","journal-title":"The American Journal of Surgical Pathology"},{"issue":"6","key":"13_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen, Y., & Yeh, M. M. (2018). Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Modern Pathology, 31(6), 965\u2013973. Epub 2018\/02\/07.","journal-title":"Modern Pathology"},{"key":"13_CR38","unstructured":"Li, M., Sack, J., Rahma, O. E., Grover, S., & Zucker, S. D. (2020). Limited utility of liver biopsy in the diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with advanced melanoma (Abstract 1197). American Association for the Study of Liver Diseases: American Association for the Study of Liver Diseases. [cited 2021 18 Feb]. Available from: https:\/\/aasld.confex.com\/aasld\/2020\/meetingapp.cgi\/Paper\/20355"},{"issue":"1","key":"13_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","volume":"36","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino, F., Vitale, G., & Ardizzoni, A. (2018). A case of nivolumab-related cholangitis and literature review: How to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Investigational New Drugs, 36(1), 144\u2013146. Epub 2017\/06\/21.","journal-title":"Investigational New Drugs"},{"issue":"3","key":"13_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino, F., Vitale, G., D\u2019Errico, A., Bertuzzi, C., Andreone, P., & Ardizzoni, A. (2017). Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury. Annals of Oncology, 28(3), 671\u2013672. Epub 2016\/12\/21.","journal-title":"Annals of Oncology"},{"issue":"3","key":"13_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama, T., Takeda, Y., Yamashita, T., et al. (2020). Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World Journal of Gastroenterology, 26(3), 353\u2013365. Epub 2020\/01\/29.","journal-title":"World Journal of Gastroenterology"},{"key":"13_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.022","volume":"115","author":"M Fouchard","year":"2019","unstructured":"Fouchard, M., Jantzem, H., Quere, G., Descourt, R., Robinet, G., & Poureau, P. G. (2019). Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. European Journal of Cancer, 115, 107\u2013110. Epub 2019\/05\/28.","journal-title":"European Journal of Cancer"},{"issue":"6","key":"13_CR43","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.31089","volume":"71","author":"L Stuart","year":"2020","unstructured":"Stuart, L., Lambourne, B., Turner, P., et al. (2020). Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma. Hepatology, 71(6), 2164\u20132166. Epub 2019\/12\/25.","journal-title":"Hepatology"},{"key":"13_CR44","unstructured":"Moi, L., Bouchaab, H., Mederos, N., et al. (2020). Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. Journal of Thoracic Oncology. Epub 2020\/09\/22."},{"issue":"18","key":"13_CR45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2217\/imt-2019-0121","volume":"11","author":"CA Reddy","year":"2019","unstructured":"Reddy, C. A., Schneider, B. J., Brackett, L. M., & Tai, A. W. (2019). Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. Immunotherapy, 11(18), 1527\u20131531. Epub 2019\/12\/04.","journal-title":"Immunotherapy"},{"issue":"3","key":"13_CR46","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/his.14000","volume":"76","author":"Y Zen","year":"2020","unstructured":"Zen, Y., Chen, Y. Y., Jeng, Y. M., Tsai, H. W., & Yeh, M. M. (2020). Immune-related adverse reactions in the hepatobiliary system: Second-generation check-point inhibitors highlight diverse histological changes. Histopathology, 76(3), 470\u2013480. Epub 2019\/09\/25.","journal-title":"Histopathology"},{"issue":"2","key":"13_CR47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","volume":"34","author":"JV Cohen","year":"2021","unstructured":"Cohen, J. V., Dougan, M., Zubiri, L., Reynolds, K. L., Sullivan, R. J., & Misdraji, J. (2021). Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathology, 34(2), 426\u2013437. Epub 2020\/09\/05.","journal-title":"Modern Pathology"},{"issue":"3","key":"13_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson, J. A., Schneider, B. J., Brahmer, J., et al. (2019). Management of immunotherapy-related toxicities, version 1.2019. Journal of the National Comprehensive Cancer Network, 17(3), 255\u2013289. Epub 2019\/03\/14.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"4","key":"13_CR49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung, V., Gupta, T., Payne, M., et al. (2019). Immunotherapy-related hepatitis: Real-world experience from a tertiary Centre. Frontline Gastroenterol, 10(4), 364\u2013371. Epub 2019\/10\/28.","journal-title":"Frontline Gastroenterol"},{"key":"13_CR50","doi-asserted-by":"crossref","unstructured":"Wang, L. S., Miller, E. D., & Zhang, H. C. (2021). Moderate dose steroid treatment for immune checkpoint inhibitor-mediated hepatotoxicity (Su327). Digestive Disease Week. Virtual.","DOI":"10.1016\/S0016-5085(21)02603-2"},{"issue":"2","key":"13_CR51","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack, C. L., Adams, D., Assis, D. N., et al. (2020). Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology, 72(2), 671\u2013722. Epub 2019\/12\/22.","journal-title":"Hepatology"},{"key":"13_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann, L., Forschner, A., Loquai, C., et al. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190\u2013209. Epub 2016\/04\/18.","journal-title":"European Journal of Cancer"},{"key":"13_CR53","doi-asserted-by":"publisher","DOI":"10.1891\/9780826172150","volume-title":"SITC\u2019s guide to managing immunotherapy toxicity","author":"MS Ernstoff","year":"2019","unstructured":"Ernstoff, M. S., Puzanov, I., Robert, C., Diab, A., & Hersey, P. (2019). SITC\u2019s guide to managing immunotherapy toxicity. In M. S. Ernstoff, I. Puzanov, C. Robert, A. Diab, & P. Hersey (Eds.). Demos Medical Publishing, an imprint of Springer Publishing Company, LLC."},{"key":"13_CR54","doi-asserted-by":"crossref","unstructured":"Ziogas, D. C., Gkoufa, A., Cholongitas, E., et al. (2020). When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report. Journal Immunother Cancer, 8(2). Epub 2020\/11\/05.","DOI":"10.1136\/jitc-2020-001322"},{"issue":"Suppl 4","key":"13_CR55","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen, J., Carbonnel, F., Robert, C., et al. (2018). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29(Suppl 4), iv264\u2013iviv6. Epub 2018\/06\/20.","journal-title":"Annals of Oncology"},{"issue":"1","key":"13_CR56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I., Diab, A., Abdallah, K., et al. (2017). Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for Immunotherapy of Cancer, 5(1), 95. Epub 2017\/11\/23.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"13_CR57","doi-asserted-by":"crossref","unstructured":"Haanen, J., Carbonnel, F., Robert, C., et al. (2017). Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28(suppl_4), iv119\u2013iiv42. Epub 2017\/09\/09.","DOI":"10.1093\/annonc\/mdx225"},{"key":"13_CR58","unstructured":"Li, M., Sack, J., Rahma, O. E., Grover, S., Zucker, S. D. (2020). Predictors and outcomes of steroid-refractory immune checkpoint inhibitor hepatitis (Abstract 0115). American Association for the Study of Liver Diseases: American Association for the Study of Liver Diseases. [cited 2021 18 Feb]. Available from: https:\/\/aasld.confex.com\/aasld\/2020\/meetingapp.cgi\/Paper\/23059"},{"issue":"8","key":"13_CR59","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018). Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: Natural progression and management. American Journal of Clinical Oncology, 41(8), 760\u2013765. Epub 2017\/07\/28.","journal-title":"American Journal of Clinical Oncology"},{"issue":"3","key":"13_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1684\/ejd.2017.2973","volume":"27","author":"K Iwamoto","year":"2017","unstructured":"Iwamoto, K., Ishitsuka, Y., Tanaka, R., Sekine, I., & Fujimoto, M. (2017). Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. European Journal of Dermatology, 27(3), 301\u2013303. Epub 2017\/05\/05.","journal-title":"European Journal of Dermatology"},{"key":"13_CR61","doi-asserted-by":"crossref","unstructured":"Eyada, M., Taggart, M. W., Wang, L. S., Miller, E. D., & Zhang, H. C. (2021). Diagnosis and characteristics of immune checkpoint inhibitor-mediated cholangiopathy: A case series. Digestive Disease Week.","DOI":"10.1016\/S0016-5085(21)02763-3"},{"issue":"4","key":"13_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty, G. J., Duckworth, A. M., Davies, S. E., et al. (2017). Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open, 2(4), e000268. Epub 2017\/10\/31.","journal-title":"ESMO Open"},{"issue":"3","key":"13_CR63","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer, M., Koukoulioti, E., Beyer, S., Simon, J. C., & Berg, T. (2017). Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. Journal of Hepatology, 66(3), 657\u2013659. Epub 2016\/12\/03.","journal-title":"Journal of Hepatology"},{"issue":"12","key":"13_CR64","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2169\/internalmedicine.9851-17","volume":"57","author":"T Matsubara","year":"2018","unstructured":"Matsubara, T., Nishida, T., Higaki, Y., et al. (2018). Nivolumab induces sustained liver injury in a patient with malignant melanoma. Internal Medicine, 57(12), 1789\u20131792. Epub 2018\/02\/13.","journal-title":"Internal Medicine"},{"issue":"1","key":"13_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack, M. H., Betof, A., Dearden, H., et al. (2018). Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology, 29(1), 250\u2013255. Epub 2017\/10\/19.","journal-title":"Annals of Oncology"},{"key":"13_CR66","doi-asserted-by":"crossref","unstructured":"Ahmed, T., Pandey, R., Shah, B., & Black, J. (2015). Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BML Case Reports, 2015. Epub 2015\/07\/16.","DOI":"10.1136\/bcr-2014-208102"},{"issue":"2","key":"13_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jjco\/hyw167","volume":"47","author":"R Tanaka","year":"2017","unstructured":"Tanaka, R., Fujisawa, Y., Sae, I., et al. (2017). Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Japanese Journal of Clinical Oncology, 47(2), 175\u2013178. Epub 2017\/02\/09.","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"13_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","volume":"1","author":"M Corrigan","year":"2019","unstructured":"Corrigan, M., Haydon, G., Thompson, F., et al. (2019). Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report. JHEP Reports, 1(1), 66\u201369. Epub 2020\/02\/11.","journal-title":"JHEP Reports"},{"key":"13_CR69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","volume":"81","author":"I Spankuch","year":"2017","unstructured":"Spankuch, I., Gassenmaier, M., Tampouri, I., et al. (2017). Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. European Journal of Cancer, 81, 203\u2013205. Epub 2017\/06\/24.","journal-title":"European Journal of Cancer"},{"key":"13_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2017.09.012","volume":"87","author":"I Spankuch","year":"2017","unstructured":"Spankuch, I., Gassenmaier, M., Tampouri, I., et al. (2017). Corrigendum to \u201csevere hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins\u201d [Eur J Cancer 81 (August 2017) 203\u2013205]. European Journal of Cancer, 87, 221. Epub 2017\/10\/08.","journal-title":"European Journal of Cancer"},{"issue":"3","key":"13_CR71","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud, C. R., Hegde, A., Cherry, C., et al. (2019). Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. Journal of Oncology Pharmacy Practice, 25(3), 551\u2013557. Epub 2017\/12\/07.","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"4","key":"13_CR72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire, H. M., Shklovskaya, E., Edwards, J., et al. (2018). Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: A case report. Cancer Immunology, Immunotherapy, 67(4), 563\u2013573. Epub 2018\/01\/01.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"3","key":"13_CR73","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","volume":"70","author":"M Riveiro-Barciela","year":"2019","unstructured":"Riveiro-Barciela, M., Munoz-Couselo, E., Fernandez-Sojo, J., Diaz-Mejia, N., Parra-Lopez, R., & Buti, M. (2019). Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? Journal of Hepatology, 70(3), 564\u2013566. Epub 2018\/12\/07.","journal-title":"Journal of Hepatology"},{"issue":"1","key":"13_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-019-0532-1","volume":"7","author":"HC Zhang","year":"2019","unstructured":"Zhang, H. C., Luo, W., & Wang, Y. (2019). Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal for Immunotherapy of Cancer, 7(1), 47. Epub 2019\/02\/20.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"13_CR75","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000471480","volume":"10","author":"K Imafuku","year":"2017","unstructured":"Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Successful treatment of sudden hepatitis induced by long-term nivolumab administration. Case Reports in Oncology, 10(1), 368\u2013371. Epub 2017\/06\/01.","journal-title":"Case Reports in Oncology"},{"issue":"21","key":"13_CR76","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Chesney, J., Pavlick, A. C., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England Journal of Medicine, 372(21), 2006\u20132017. Epub 2015\/04\/22.","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"13_CR77","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","volume":"69","author":"ML Gauci","year":"2018","unstructured":"Gauci, M. L., Baroudjian, B., Zeboulon, C., et al. (2018). Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? Journal of Hepatology, 69(2), 548\u2013550. Epub 2018\/05\/12.","journal-title":"Journal of Hepatology"},{"issue":"4","key":"13_CR78","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2018.06.012","volume":"69","author":"P Bhave","year":"2018","unstructured":"Bhave, P., Buckle, A., Sandhu, S., & Sood, S. (2018). Mortality due to immunotherapy related hepatitis. Journal of Hepatology, 69(4), 976\u2013978. Epub 2018\/08\/11.","journal-title":"Journal of Hepatology"},{"issue":"7","key":"13_CR79","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/pin.12812","volume":"69","author":"O Inamori","year":"2019","unstructured":"Inamori, O., Miyagawa-Hayashino, A., Ueno, A., et al. (2019). Fulminant hepatitis as an immune-related adverse event after nivolumab treatment. Pathology International, 69(7), 434\u2013436. Epub 2019\/07\/10.","journal-title":"Pathology International"},{"issue":"2","key":"13_CR80","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1159\/000507695","volume":"13","author":"T Thorsteinsdottir","year":"2020","unstructured":"Thorsteinsdottir, T., Loitegard, T., Reims, H. M., & Porojnicu, A. C. (2020). Fatal cholestatic liver injury during treatment with PD1 immune checkpoint inhibitor for malignant melanoma: A case report. Case Reports in Oncology, 13(2), 659\u2013663. Epub 2020\/08\/11.","journal-title":"Case Reports in Oncology"},{"issue":"12","key":"13_CR81","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y., Salem, J. E., Cohen, J. V., et al. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncology, 4(12), 1721\u20131728. Epub 2018\/09\/23.","journal-title":"JAMA Oncology"},{"issue":"51","key":"13_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009431","volume":"96","author":"Z Wu","year":"2017","unstructured":"Wu, Z., Lai, L., Li, M., Zhang, L., & Zhang, W. (2017). Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report. Medicine (Baltimore), 96(51), e9431. Epub 2018\/02\/03.","journal-title":"Medicine (Baltimore)"},{"issue":"23","key":"13_CR83","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1002\/cncr.33165","volume":"126","author":"M Li","year":"2020","unstructured":"Li, M., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2020). Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer, 126(23), 5088\u20135097. Epub 2020\/09\/06.","journal-title":"Cancer"},{"issue":"1","key":"13_CR84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H., Tran, C. N., Ge, P. S., et al. (2019). Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. Journal for Immunotherapy of Cancer, 7(1), 118. Epub 2019\/05\/06.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"13_CR85","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","volume":"13","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Sun, J. M., Lee, S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2018). Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. Journal of Thoracic Oncology, 13(3), e34\u2013ee6. Epub 2018\/02\/24.","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"13_CR86","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami, H., Tanizaki, J., Tanaka, K., et al. (2017). Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs, 35(4), 529\u2013536. Epub 2017\/03\/21.","journal-title":"Investigational New Drugs"},{"key":"13_CR87","doi-asserted-by":"publisher","first-page":"1027323","DOI":"10.1155\/2018\/1027323","volume":"2018","author":"Q Su","year":"2018","unstructured":"Su, Q., Zhang, X. C., Zhang, C. G., Hou, Y. L., Yao, Y. X., & Cao, B. W. (2018). Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: Systematic assessment with meta-analysis. Journal of Immunology Research, 2018, 1027323. Epub 2018\/07\/05.","journal-title":"Journal of Immunology Research"},{"issue":"1","key":"13_CR88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H., Tang, T., Lu, Y., et al. (2019). Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Journal for Immunotherapy of Cancer, 7(1), 31. Epub 2019\/02\/08.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"4","key":"13_CR89","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","volume":"19","author":"J George","year":"2019","unstructured":"George, J., Bajaj, D., Sankaramangalam, K., et al. (2019). Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology, 19(4), 587\u2013594. Epub 2019\/05\/12.","journal-title":"Pancreatology"},{"issue":"2","key":"13_CR90","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","volume":"41","author":"JM Michot","year":"2018","unstructured":"Michot, J. M., Ragou, P., Carbonnel, F., et al. (2018). Significance of immune-related lipase increase induced by Antiprogrammed Death-1 or death Ligand-1 antibodies: A brief communication. Journal of Immunotherapy, 41(2), 84\u201385. Epub 2017\/12\/19.","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"13_CR91","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016). Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clinical Cancer Research, 22(4), 886\u2013894. Epub 2015\/10\/09.","journal-title":"Clinical Cancer Research"},{"key":"13_CR92","doi-asserted-by":"crossref","unstructured":"Friedman, C. F., Clark, V., Raikhel, A. V., et al. (2017). Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab. Journal of the National Cancer Institute, 109(4). Epub 2017\/01\/04.","DOI":"10.1093\/jnci\/djw260"},{"issue":"9","key":"13_CR93","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/MEG.0000000000001852","volume":"32","author":"S Khurana","year":"2020","unstructured":"Khurana, S., Chi Zhang, H., Peng, Y., Lu, Y., & Wang, Y. (2020). Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. European Journal of Gastroenterology & Hepatology, 32(9), 1266\u20131267. Epub 2020\/08\/03.","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"13_CR94","doi-asserted-by":"publisher","first-page":"S694","DOI":"10.14309\/01.ajg.0000707884.05320.32","volume":"115","author":"P Goyal","year":"2020","unstructured":"Goyal, P., Moyers, J. T., Hammami, M. B., & Elgohary, B. G. (2020). S1459 immune checkpoint inhibitor-induced pancreatic injury: An atypical presentation. Official Journal of the American College of Gastroenterology | ACG, 115, S694.","journal-title":"Official Journal of the American College of Gastroenterology | ACG"},{"key":"13_CR95","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.14309\/01.ajg.0000702416.63728.3c","volume":"115","author":"D Satish","year":"2020","unstructured":"Satish, D., Gerdes, H., & Faleck, D. (2020). S0092\u2003exocrine pancreatic insufficiency induced by immune checkpoint inhibitors: A case series. Official journal of the American College of Gastroenterology | ACG, 115, S44.","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"13_CR96","doi-asserted-by":"publisher","first-page":"S686","DOI":"10.14309\/00000434-201710001-01260","volume":"112","author":"HC Zhang","year":"2017","unstructured":"Zhang, H. C., & Miller, E. (2017). Immune-related pancreatitis secondary to ipilimumab and nivolumab in a patient with melanoma: 1259. Official Journal of the American College of Gastroenterology | ACG, 112, S686.","journal-title":"Official Journal of the American College of Gastroenterology | ACG"},{"issue":"2","key":"13_CR97","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1503\/cjs.015015","volume":"59","author":"JA Greenberg","year":"2016","unstructured":"Greenberg, J. A., Hsu, J., Bawazeer, M., et al. (2016). Clinical practice guideline: Management of acute pancreatitis. Canadian Journal of Surgery, 59(2), 128\u2013140. Epub 2016\/03\/24.","journal-title":"Canadian Journal of Surgery"},{"issue":"5","key":"13_CR98","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/CMR.0000000000000611","volume":"29","author":"J Kohlmann","year":"2019","unstructured":"Kohlmann, J., Wagenknecht, D., Simon, J. C., & Ziemer, M. (2019). Immune-related pancreatitis associated with checkpoint blockade in melanoma. Melanoma Research, 29(5), 549\u2013552. Epub 2019\/04\/10.","journal-title":"Melanoma Research"},{"issue":"3","key":"13_CR99","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/imt-2017-0126","volume":"10","author":"T Prasanna","year":"2018","unstructured":"Prasanna, T., McNeil, C. M., Nielsen, T., & Parkin, D. (2018). Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy, 10(3), 171\u2013175. Epub 2018\/01\/27.","journal-title":"Immunotherapy"},{"key":"13_CR100","doi-asserted-by":"crossref","unstructured":"Dougan, M., Wang, Y., Rubio-Tapia, A., Lim, J.K. (2021). AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 160(4), 1384\u20131393.","DOI":"10.1053\/j.gastro.2020.08.063"},{"key":"13_CR101","doi-asserted-by":"crossref","unstructured":"Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., et al. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for Immunotherapy of Cancer, 9(6), e002435.","DOI":"10.1136\/jitc-2021-002435"}],"container-title":["Advances in Experimental Medicine and Biology","Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-79308-1_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T03:30:59Z","timestamp":1676086259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-79308-1_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030793074","9783030793081"],"references-count":101,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-79308-1_13","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"1 January 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}